The Patient Outcomes With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Receiving Aumolertinib As First-Line Treatment

    June 2024 in “ Journal of Clinical Oncology ”
    Jisheng Li, Zhao Wen, Hongxin Li, Tiantian Xuan, Chengjun Wang, Rongyu Zhang, Chuang Yang, Jian Wang, Cuihua Yi
    Image of study
    TLDR Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
    In a study involving 33 patients with advanced NSCLC and EGFR mutations, aumolertinib as a first-line treatment showed promising results. The objective response rate was 65.2%, and the disease control rate was 91.3%. Patients experienced improvements in general health status, functional status, and key symptoms such as cough, sore mouth or tongue, and pain, as measured by EORTC quality of life questionnaires. These findings align with the AENEAS trial, indicating that aumolertinib is effective and well-tolerated, although the long-term progression-free and overall survival rates are yet to be determined.
    Discuss this study in the Community →